Selected research
Market Structure
Global Metabotropic Glutamate Receptor 7 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Metabotropic Glutamate Receptor 7 market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Metabotropic Glutamate Receptor 7 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Metabotropic Glutamate Receptor 7 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Metabotropic Glutamate Receptor 7 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Metabotropic Glutamate Receptor 7 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Metabotropic Glutamate Receptor 7 include Addex Therapeutics Ltd, Aevi Genomic Medicine Inc, Bio-Pharm Solutions Co Ltd and Pragma Therapeutics SAS, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Metabotropic Glutamate Receptor 7 market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Metabotropic Glutamate Receptor 7 and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Metabotropic Glutamate Receptor 7 sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Metabotropic Glutamate Receptor 7 market size, projected growth trends, production technologies, key applications, and end-use industries.
Metabotropic Glutamate Receptor 7 Segment by Company
Addex Therapeutics Ltd
Aevi Genomic Medicine Inc
Bio-Pharm Solutions Co Ltd
Pragma Therapeutics SAS
Metabotropic Glutamate Receptor 7 Segment by Type
PGT-117
JBPOS-0101
ADX-71743
Others
Metabotropic Glutamate Receptor 7 Segment by Application
Infantile Spasm
Generalized Anxiety Disorder
Status Epilepticus
Others
Metabotropic Glutamate Receptor 7 Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Metabotropic Glutamate Receptor 7 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Metabotropic Glutamate Receptor 7 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Metabotropic Glutamate Receptor 7.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Metabotropic Glutamate Receptor 7 market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Metabotropic Glutamate Receptor 7 manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Metabotropic Glutamate Receptor 7 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Metabotropic Glutamate Receptor 7 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- PGT-117
- JBPOS-0101
- ADX-71743
- Others
Applications
- Infantile Spasm
- Generalized Anxiety Disorder
- Status Epilepticus
- Others
Companies covered
- Addex Therapeutics Ltd
- Aevi Genomic Medicine Inc
- Bio-Pharm Solutions Co Ltd
- Pragma Therapeutics SAS
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Metabotropic Glutamate Receptor 7 Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Metabotropic Glutamate Receptor 7 Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Metabotropic Glutamate Receptor 7 Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Metabotropic Glutamate Receptor 7 Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Metabotropic Glutamate Receptor 7 Market Dynamics
- 2.1 Metabotropic Glutamate Receptor 7 Industry Trends
- 2.2 Metabotropic Glutamate Receptor 7 Industry Drivers
- 2.3 Metabotropic Glutamate Receptor 7 Industry Opportunities and Challenges
- 2.4 Metabotropic Glutamate Receptor 7 Industry Restraints
3 Metabotropic Glutamate Receptor 7 Market by Manufacturers
- 3.1 Global Metabotropic Glutamate Receptor 7 Revenue by Manufacturers (2021-2026)
- 3.2 Global Metabotropic Glutamate Receptor 7 Sales by Manufacturers (2021-2026)
- 3.3 Global Metabotropic Glutamate Receptor 7 Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Metabotropic Glutamate Receptor 7 Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Metabotropic Glutamate Receptor 7 Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Metabotropic Glutamate Receptor 7 Manufacturers, Product Type & Application
- 3.7 Global Metabotropic Glutamate Receptor 7 Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Metabotropic Glutamate Receptor 7 Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Metabotropic Glutamate Receptor 7 Players Market Share by Revenue in 2025
- 3.8.3 2025 Metabotropic Glutamate Receptor 7 Tier 1, Tier 2, and Tier 3
4 Metabotropic Glutamate Receptor 7 Market by Type
- 4.1 Metabotropic Glutamate Receptor 7 Type Introduction
- 4.1.1 PGT-117
- 4.1.2 JBPOS-0101
- 4.1.3 ADX-71743
- 4.1.4 Others
- 4.2 Global Metabotropic Glutamate Receptor 7 Sales by Type
- 4.2.1 Global Metabotropic Glutamate Receptor 7 Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Metabotropic Glutamate Receptor 7 Sales by Type (2021-2032)
- 4.2.3 Global Metabotropic Glutamate Receptor 7 Sales Market Share by Type (2021-2032)
- 4.3 Global Metabotropic Glutamate Receptor 7 Revenue by Type
- 4.3.1 Global Metabotropic Glutamate Receptor 7 Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Metabotropic Glutamate Receptor 7 Revenue by Type (2021-2032)
- 4.3.3 Global Metabotropic Glutamate Receptor 7 Revenue Market Share by Type (2021-2032)
5 Metabotropic Glutamate Receptor 7 Market by Application
- 5.1 Metabotropic Glutamate Receptor 7 Application Introduction
- 5.1.1 Infantile Spasm
- 5.1.2 Generalized Anxiety Disorder
- 5.1.3 Status Epilepticus
- 5.1.4 Others
- 5.2 Global Metabotropic Glutamate Receptor 7 Sales by Application
- 5.2.1 Global Metabotropic Glutamate Receptor 7 Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Metabotropic Glutamate Receptor 7 Sales by Application (2021-2032)
- 5.2.3 Global Metabotropic Glutamate Receptor 7 Sales Market Share by Application (2021-2032)
- 5.3 Global Metabotropic Glutamate Receptor 7 Revenue by Application
- 5.3.1 Global Metabotropic Glutamate Receptor 7 Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Metabotropic Glutamate Receptor 7 Revenue by Application (2021-2032)
- 5.3.3 Global Metabotropic Glutamate Receptor 7 Revenue Market Share by Application (2021-2032)
6 Global Metabotropic Glutamate Receptor 7 Sales by Region
- 6.1 Global Metabotropic Glutamate Receptor 7 Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Metabotropic Glutamate Receptor 7 Sales by Region (2021-2032)
- 6.2.1 Global Metabotropic Glutamate Receptor 7 Sales by Region (2021-2026)
- 6.2.2 Global Metabotropic Glutamate Receptor 7 Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Metabotropic Glutamate Receptor 7 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Metabotropic Glutamate Receptor 7 Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Metabotropic Glutamate Receptor 7 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Metabotropic Glutamate Receptor 7 Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Metabotropic Glutamate Receptor 7 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Metabotropic Glutamate Receptor 7 Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Metabotropic Glutamate Receptor 7 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Metabotropic Glutamate Receptor 7 Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Metabotropic Glutamate Receptor 7 Revenue by Region
- 7.1 Global Metabotropic Glutamate Receptor 7 Revenue by Region
- 7.1.1 Global Metabotropic Glutamate Receptor 7 Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Metabotropic Glutamate Receptor 7 Revenue by Region (2021-2026)
- 7.1.3 Global Metabotropic Glutamate Receptor 7 Revenue by Region (2027-2032)
- 7.1.4 Global Metabotropic Glutamate Receptor 7 Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Metabotropic Glutamate Receptor 7 Revenue (2021-2032)
- 7.2.2 North America Metabotropic Glutamate Receptor 7 Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Metabotropic Glutamate Receptor 7 Revenue (2021-2032)
- 7.3.2 Europe Metabotropic Glutamate Receptor 7 Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Metabotropic Glutamate Receptor 7 Revenue (2021-2032)
- 7.4.2 Asia-Pacific Metabotropic Glutamate Receptor 7 Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Metabotropic Glutamate Receptor 7 Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Metabotropic Glutamate Receptor 7 Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Addex Therapeutics Ltd
- 8.1.1 Addex Therapeutics Ltd Company Information
- 8.1.2 Addex Therapeutics Ltd Business Overview
- 8.1.3 Addex Therapeutics Ltd Metabotropic Glutamate Receptor 7 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Addex Therapeutics Ltd Metabotropic Glutamate Receptor 7 Product Portfolio
- 8.1.5 Addex Therapeutics Ltd Recent Developments
- 8.2 Aevi Genomic Medicine Inc
- 8.2.1 Aevi Genomic Medicine Inc Company Information
- 8.2.2 Aevi Genomic Medicine Inc Business Overview
- 8.2.3 Aevi Genomic Medicine Inc Metabotropic Glutamate Receptor 7 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Aevi Genomic Medicine Inc Metabotropic Glutamate Receptor 7 Product Portfolio
- 8.2.5 Aevi Genomic Medicine Inc Recent Developments
- 8.3 Bio-Pharm Solutions Co Ltd
- 8.3.1 Bio-Pharm Solutions Co Ltd Company Information
- 8.3.2 Bio-Pharm Solutions Co Ltd Business Overview
- 8.3.3 Bio-Pharm Solutions Co Ltd Metabotropic Glutamate Receptor 7 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Bio-Pharm Solutions Co Ltd Metabotropic Glutamate Receptor 7 Product Portfolio
- 8.3.5 Bio-Pharm Solutions Co Ltd Recent Developments
- 8.4 Pragma Therapeutics SAS
- 8.4.1 Pragma Therapeutics SAS Company Information
- 8.4.2 Pragma Therapeutics SAS Business Overview
- 8.4.3 Pragma Therapeutics SAS Metabotropic Glutamate Receptor 7 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Pragma Therapeutics SAS Metabotropic Glutamate Receptor 7 Product Portfolio
- 8.4.5 Pragma Therapeutics SAS Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Metabotropic Glutamate Receptor 7 Value Chain Analysis
- 9.1.1 Metabotropic Glutamate Receptor 7 Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Metabotropic Glutamate Receptor 7 Production Mode & Process
- 9.2 Metabotropic Glutamate Receptor 7 Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Metabotropic Glutamate Receptor 7 Distributors
- 9.2.3 Metabotropic Glutamate Receptor 7 Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst